Ovarian Cancers : Advances through International Research Cooperation (GINECO, ENGOT, GCIG)
https://libcat.nshealth.ca/en/permalink/provcat41313
Eric Pujade-Lauraine, Isabelle Ray-Coquard, Fabrice Lécuru, editors.
--Cham:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing n…
- Available Online
- View e-Book
- Other Authors
- Pujade-Lauraine, Eric
- Ray-Coquard, Isabelle
- Lécuru, Fabrice
- Responsibility
- Eric Pujade-Lauraine, Isabelle Ray-Coquard, Fabrice Lécuru, editors
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (x, 286 pages) : 12 illus., 9 illus. in color
- ISBN
- 9783319321103
- 9783319321080 (print ed.)
- Subjects (MeSH)
- International Cooperation
- Ovarian Neoplasms - therapy
- Treatment Outcome
- Abstract
- This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing novel drug combinations. Over recent years, ovarian cancer management has embraced molecular biology. It is now more correct to talk about cancers of the ovary rather than ovarian cancer, since it is not a unique disease but several entities with different molecular drivers. The significant advances in drugs targeting the microenvironment or the tumor cell DNA repair mechanisms are presented in detail together with exciting future perspectives. All these advances would not have been possible without collaborative groups such as the GINECO group in France and their integration in wider clinical research networks at the European (ENGOT) and international (GCIG) level.
- Contents
- Part I: Ovarian Cancer Management -- 1. Clinical Research in France, Europe, and in the World Dedicated to Ovarian Cancers -- 2. Genetics of Ovarian Carcinomas -- 3. Debulking Surgery: Interval Debulking Surgery Versus Primary: Pros and Cons on How to Evaluate Quality -- 4. How to Evaluate Tumor Burden Before Therapeutic Decision -- 5. Value of Lymphadenectomy -- 6. Ovarian Cancer and HIPEC: In the Era of Evidence Based Medicine -- 7. Oncofertility Applied to Epithelial Ovarian Cancer -- 8. First-Line Systemic Therapy (Chemo/Antiangiogenics) -- 9. Ovarian Cancer in the Elderly -- 10. Treatment at Relapse (Surgery and Systemic Treatments) -- 11. The Future in Ovarian Cancer: Advances in Immunotherapies -- Part II: Particular Types of Ovarian Cancers -- 12. High-Grade Carcinomas, BRCA Mutations and the Role of PARP Inhibitors -- 13. Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary or Peritoneum -- 14. Clear Cell Carcinoma -- 15. Endometrioid Carcinoma of the Ovary -- 16. Mucinous Carcinoma of the Ovary -- 17. Gynecological Carcinosarcomas -- 18. Malignant Ovarian Germ Cell Tumours: An Overview of Management and Controversies -- 19. Ovarian Sex Cord Tumors -- 20. Small Cell Carcinoma of the Ovary.
- Format
- e-Book
- Location
- Online
